helix biomedix inc (HXBM:OTC US)
helix biomedix inc (HXBM) Snapshot
|
Open
$24.50
|
Previous Close
$24.00
|
|
|
Day High
$24.50
|
Day Low
$24.50
|
|
|
52 Week High
05/31/12 - $132.00
|
52 Week Low
05/31/12 - $7.69
|
|
|
Market Cap
4.1M
|
Average Volume 10 Days
20.0
|
|
|
EPS TTM
$-15.00
|
Shares Outstanding
165.7K
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
helix biomedix inc (HXBM) Related Businessweek News
No Related Businessweek News Foundhelix biomedix inc (HXBM) Details
Helix BioMedix, Inc., a biopharmaceutical company, engages in the development and commercialization of bioactive small molecule peptides. The company is involved in licensing rights to third parties to use selected proprietary peptides in specific fields of application, as well as commercializing its own branded products. It offers a range of cosmeceutical peptides and small molecule technologies capable of improving various aspects of the skin’s appearance, texture, tone, and barrier function. The company supplies and licenses its cosmeceutical peptides to skin care contract manufacturers and materials suppliers for inclusion in their acne treatment, anti-aging skin care, color cosmetic, and specialty body care products. It also develops anti-infective peptides for the treatment of skin and wound infections, and the prevention of staphylococcus aureus infections, including those caused by methicillin resistant staphylococcus aureus. The company was founded in 1988 and is headquartered in Bothell, Washington.
helix biomedix inc (HXBM) Top Compensated Officers
helix biomedix inc (HXBM) Key Developments
Helix Biomedix Inc., Special/Extraordinary Shareholders Meeting, Mar 11, 2013.
Helix Biomedix Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock, $0.001 par value per share under the Securities Exchange Act of 1934, as amended.
Helix Biomedix Inc. at its special meeting of stockholders to be held on December 28, 2012, will approve the proposal to amend company's Certificate of Incorporation to effect a 1-for-300 reverse stock split of company's common stock, par value $0.001 per share.
| Recently Viewed | |||
| HXBM:US | $24.50 USD | +0.50 | |
| Company | Last | Change |
| Croda International PLC | 2,521 GBp | -17.00 |
| Koninklijke DSM NV | €47.44 EUR | -0.18 |
| Lonza Group AG | SFr.72.35 CHF | -0.15 |
| View Industry Companies | ||
Industry Analysis
HXBM
Industry Average
| Valuation | HXBM | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 1.9x |
|
| Price/Book | 3.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 1.8x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact HELIX BIOMEDIX INC, please visit www.helixbiomedix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








